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Abstract 
Background: It is well recognised that access and receipt of appropriate guideline recommended treatment with 
systemic anti-cancer therapies for secondary breast cancer is a key determinant in overall survival. Where there is 
disparity in access this may result in unwarranted variation and disparity in outcomes. Individual, clinical and wider 
contextual factors have been associated with these disparities, however this remains poorly understood for women 
with secondary breast cancer. The purpose of the review is to examine individual, clinical and contextual factors 
which influence access to evidence-based systemic anti-cancer therapies for women with secondary breast cancer. 
This will include barriers and facilitators for access and receipt of treatment and an exploration of women and clini-
cians experience and perspectives on access.
Methods: A mixed methods approach with a segregated design will be used to examine and explore factors which 
influence access to systemic anti-cancer therapies for women with secondary breast cancer. Electronic databases to 
be searched from January 2000 onwards will be EBSCO CINAHL Plus, Ovid MEDLINE, Ovid EMBASE, PsychINFO and the 
Cochrane Library and JBI database. This will include NHS Evidence which will be searched for unpublished studies and 
gray literature.
Title and abstract citations and full-text articles will be screened by the author and second reviewer. Data will be 
extracted by the author and validated by the second reviewer.
An overarching synthesis will be produced which brings together quantitative and qualitative findings. Methodologi-
cal quality and risk of bias will be assessed using the Mixed Methods Appraisal Tool.
Discussion: Understanding individual, clinical and wider contextual factors associated with access and receipt of 
systemic anti-cancer therapies for secondary breast cancer is a complex phenomenon. These will be examined to 
determine any association with access. Review findings will be used to guide future research in this area and the 
development of an evidence-based service level intervention designed to address unwarranted variation in access 
based upon the Medical Research Council (MRC) approach to the development, implementation and evaluation of 
complex interventions.
Systematic review registration: The review protocol has been registered in PROSPERO CRD42 02019 6490.
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Background
Equity in access is a global health priority with adequate 
and fair access being fundamental to the organisation 
and delivery of high quality health services. Equity of 
access was considered to be one of the founding princi-
ples of the NHS with equitable access to treatment being 
essential to promote and preserve health [1]. Equity of 
access is a central component of the UK National Can-
cer Programme [2] however it is acknowledged that there 
remains inequity and unwarranted variation in access to 
treatment across the UK, which disproportionately influ-
ences health outcomes [3, 4]. With regard to cancer treat-
ment it is accepted that access and receipt of appropriate 
therapy is a key determinant in improving outcomes. 
Conversely a number of factors have been identified 
as influencing access. However no attempt to date has 
been made to evaluate factors commonly associated 
with access to systemic anti-cancer therapies (SACT) for 
women with secondary breast cancer (SBC).
SBC has been defined as the development of new 
tumours in tissues and organs away from the primary 
tumour site [5] with the most common sites of metastases 
being lungs, liver, bones, and brain. It is estimated that up to 
30% of women with primary breast cancer will experience 
disease recurrence following initial treatment and despite 
the increasing effectiveness of treatments, median overall 
survival is estimated at 3 years with no statistically signifi-
cant improvement in the past twenty years [6]. SBC repre-
sents a significant disease burden with high levels of unmet 
need and unwarranted variation in outcomes [4]. Dispari-
ties have been reported across the breast cancer continuum 
which have compromised proper access to and receipt 
of services, however this remains poorly understood for 
women with SBC [7]. Guideline recommended SACT for 
the treatment of SBC is intended to optimize patient care 
informed by the best available evidence and an assessment 
of the benefits and harms of alternative treatment options. 
Treatment aims to improve long term survival, increase 
progression free survival and improve quality of life, though 
is seldom used with curative intent [8]. Current guidelines 
for SACT treatment for SBC are set out internationally, 
nationally and regionally and for the purposes of the review 
guideline recommended SACT are those which have been 
recommended by National, regional and local bodies.
From a theoretical perspective access has been defined 
as the “degree of fit between clients and the system” char-
acterised by dimensions of availability, accessibility, accom-
modation, affordability and acceptability [9]. A more 
contemporary, patient centred framework where multi-level 
determinants related to health systems, institutions, organi-
sations and providers are considered alongside factors at the 
individual, household, community, and population levels 
[10] will provide a theoretical basis for the review.
Review findings will be used to inform the develop-
ment of an evidence-based service level intervention, 
based upon the UK Medical Research Council (MRC) 
approach to the development, implementation and 
evaluation of complex interventions [11]. The interven-
tion will be designed to promote greater standardisation 
and a reduction in unwarranted variation in access and 
receipt of treatment. To achieve this, the review aims 
to identify the available evidence to investigate factors 
which influence access to guideline recommended treat-
ment with systemic anti-cancer therapies for women 
with secondary breast cancer. This will include the iden-
tification of barriers and enabling factors and explore 
women and clinicians experience of access and treat-
ment receipt for SBC.
Methods
The protocol is reported in accordance with the 
PRISMA-P statement [12] (see Additional file 1) and has 
been registered with the International Prospective Reg-
ister of Systematic Reviews (PROSPERO) registration 
number PROSPERO CRD42020196490.
Aim, design and setting
The review will adopt a mixed methods approach applying 
a segregated design which will maintain the conventional 
binary distinction between the qualitative and quantita-
tive paradigm, with integration of each distinct synthesis. 
The quantitative component aims to identify and investi-
gate those factors associated with access and treatment. 
This will be complimented by the qualitative component 
which aims to explore how women with secondary breast 
cancer and their clinicians experience access and receipt 
of SACT (Table 1.). In particular to explore barriers and 
facilitators related to individual, clinical and wider contex-
tual factors relating to health care systems and geographi-
cal location. A mixed method approach will be taken as 
access to treatment is a complex, multi-faceted phenom-
ena which requires a comprehensive, patient centred 
understanding of how and why and in what context any 
association exists. This is conducive to a more sophisti-
cated integration of the traditional quantitative and quali-
tative paradigms offered by a mixed methods approach.
The review setting and context reflects the mixed 
method approach and will consider studies which explore 
multi-level factors which have previously been associated 
with access to treatment. The review will consider stud-
ies which investigate and explore access to SACT, includ-
ing chemotherapy, targeted therapy, immunotherapy and 
hormone/endocrine therapy. This will include studies 
which report across secondary, tertiary, specialist and 
palliative care centres, where SACT is accessed as either, 
first, second or subsequent line of treatment.
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Study eligibility
Criteria for study eligibility were developed to address 
the aims of the review and are set out in Table 1.
Search strategy and information sources
A modified PICO framework was used to develop the 
review question [13]. This was then used to formulate 
the search strategy by identifying key concepts, subject 
headings and keywords (see example search strategy 
in Additional file  2). A preliminary search was under-
taken to identify articles on the topic with text words 
in titles and abstracts of relevant articles. This was then 
used to develop a full search strategy. The search strat-
egy including all identified keywords and index terms will 
be tailored to each information source. The electronic 
databases to be searched will be The Cochrane Library, 
EBSCO CINAHL Plus, Ovid MEDLINE, Ovid EMBASE, 
PsychINFO. Searches will be conducted from 1 January 
2000 onwards. Reference lists of included studies will also 
be screened. The basic search strategy will be tailored to 
individual databases and undertaken with the support of 
an experienced librarian/evidence specialist. Grey litera-
ture will be searched using NHS Evidence.
Study screening and selection
Records will be stored and managed in EndNote X9. 
Titles and abstracts will be screened against the inclusion 
and exclusion criteria. Potentially eligible studies will be 
retrieved in full. Full text articles will then be assessed 
against the inclusion and exclusion criteria, with reasons 
for exclusion recorded and reported. Screening and full 
text assessment will be undertaken by two independent 
reviewers with any disagreement resolved through dis-
cussion. Where consensus cannot be reached this will be 
achieved through arbitration with a third reviewer. The 
results of the search will be reported in full in the final 
report and presented in a Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) flow 
diagram [14].
Data extraction
Data will be extracted using an adaptation of a stand-
ardized data extraction tool which will be piloted prior 
to commencement of full data extraction. Data will be 
extracted for author, year of publication, study design, 
setting, country, primary data source and study popula-
tion. Baseline population demographics will be extracted 
with primary exposure variables and covariates. Clinical 
characteristics will be extracted for diagnosis, clinical sub 
type of disease i.e. hormone receptor and HER2 status, 
performance status and comorbidities. Contextual fac-
tors for geographical location, population density and 
place of care will be extracted where reported. No data 
assumptions and simplifications are planned. Main find-
ings will be extracted and assigned a level of credibility 
based upon methodological quality and risk of bias.
Assessment of methodological quality and risk of bias
Methodological quality of included studies will be 
assessed using the Mixed Methods Appraisal Tool 
(MMAT) [15]. This will be undertaken by two independ-
ent reviewers with any disagreement resolved through 
discussion or where required with arbitration from a third 
reviewer. This process will be followed for quantitative 
and qualitative studies. The results of critical appraisal will 
be reported in narrative form accompanied by a summary 
table. Risk of bias for included studies will be classified as 
low risk, high risk, or unclear (either lack of information 
or uncertainty over the potential for bias). The Cochrane 
Collaboration tool for assessing risk of bias will be used 
for included randomised controlled trials and the prelimi-
nary risk of bias in non-randomised studies—of exposures 
(ROBINS-E) tool will be used for non-randomised inter-
ventional studies [16, 17]. Studies will not be excluded 
based upon low methodological quality or credibility, 
however this will be reflected in the analysis and synthesis.
Data analysis, synthesis and integration
The review will follow a segregated approach to analysis 
and synthesis. This will involve distinct quantitative and 
qualitative analysis and synthesis followed by integra-
tion of the resultant evidence. Analysis and synthesis of 
quantitative included studies will be presented in nar-
rative form together with tables and figures to aid data 
presentation. The narrative will be structured around 
multi-level factors which have shown an association with 
access and receipt of treatment as the primary outcome 
measure for the review. This will be determined a priori 
guided by the theoretical model of access adopted to 
guide the review [10]. Factors associated with access and 
receipt will be classified as individual, clinical and con-
textual. Where possible data will be pooled using statisti-
cal meta-analysis. This will be undertaken in accordance 
with guidance for meta-analysis of observational studies 
where appropriate. Heterogeneity will be assessed using 
the standard chi squared and I2 tests [18]. Analyses will 
be performed using a random effects model to estimate 
a summary measure of access and treatment receipt for 
each factor, with an overall summary measure of the like-
lihood of receipt of treatment for each included study. 
Qualitative findings will be presented in narrative form 
using a narrative synthesis approach [19]. Where pos-
sible these will be pooled using meta-aggregation to 
produce a comprehensive set of synthesized qualitative 
findings. Final synthesis of quantitative and qualitative 
findings will combine the separate synthesis into a set 
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of conclusions which will reflect the narrative synthesis 
of qualitative findings and the quantitative findings pro-
duced from meta-analysis (where appropriate) to config-
ure a mixed research synthesis.
Discussion
Understanding multi-level factors associated with access 
and receipt of SACT for SBC is a complex phenom-
enon. Examining these factors in a comprehensive way 
will enable the development of evidence based strate-
gies to address the challenges which they may present. 
It is acknowledged that appropriate access is a key deter-
minant in overall survival, yet disparities have compro-
mised proper access to and receipt of services resulting 
in unwarranted variation in outcomes. However, the 
extent of these disparities, the underlying reasons and the 
impact on outcomes remains poorly understood. Several 
theoretical frameworks have been proposed to concep-
tualise access. The multi-level factors and complexity of 
SACT treatment pathways for SBC led to the selection of 
a patient centred model of access to guide the review. The 
model was selected as it provided a contemporary per-
spective on access based on a synthesis of the published 
literature. The model incorporated dimensions of acces-
sibility which represent supply, which when integrated 
with the corresponding abilities of persons to interact, 
generate access. The review will address those individual 
and clinical characteristics which influence the ability of 
individuals to interact with dimensions of accessibility to 
create access alongside dimensions of accessibility relat-
ing to wider contextual factors, including organisational 
and health care systems factors.
Practical issues in the conduct of the review may 
include identification of potentially eligible studies 
which may be compounded by the diversity of reported 
factors and characteristics within and between stud-
ies. There may be potential challenges in accurately and 
consistently identifying and quantifying multi-level fac-
tors which may be associated with access. Additionally 
the range of included study designs may present chal-
lenges in the assessment of methodological quality and 
subsequent analysis and synthesis. The review protocol 
has been designed to address these issues and minimise 
the impact in the conduct of the review. Conversely the 
complexity of the review question meant this could be 
most appropriately answered using a mixed methods 
approach, in particular a segregated design where quali-
tative and quantitative findings are viewed distinctly as 
complementary and synthesis is configurative.
Potential limitations may include high levels of het-
erogeneity between studies which may preclude statisti-
cal meta-analysis of included quantitative studies. There 
may be limited qualitative and mixed method studies 
identified in the topic area which would limit the poten-
tial for configurative synthesis and integration of quanti-
tative and qualitative findings at review level. There may 
be potential challenges in accurately and consistently 
identifying and quantifying multi-level factors which may 
be associated with access. From a methodological per-
spective this will be addressed using narrative synthesis 
and where appropriate, sub group analysis for each fac-
tor to determine the extent and significance of the asso-
ciation. This will be further explored in the qualitative 
analysis and brought together through the synthesis. The 
inclusion of observational studies considerably expands 
the challenges in establishing a level of inference with a 
greater risk of confounding resulting from selection bias. 
Additionally, including only references published in Eng-
lish could lead to selection and reporting bias, which will 
be addressed through the analysis. Any amendments 
made to this protocol when conducting the review will be 
outlined in PROSPERO and reported in the final manu-
script. In summary, the importance and significance of 
answering the review question outweighs the balance of 
the potential limitations. The impact of these have been 
reflected in the methodology and will be accounted for 
and addressed in the analysis, synthesis and integration 
of findings.
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